ROS1
抑制剂选择性比较
ROS1产品
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S1068 |
Crizotinib (PF-02341066)Crizotinib (PF-02341066) 克唑替尼是一种有效的c-Met和ALK抑制剂，在细胞试验中IC50分别为11 nM 和 24 nM。它同时也是有效的ROS1抑制剂，其Ki值小于0.025 nM。Crizotinib可在多种肺癌细胞系中通过抑制STAT3通路来诱导自噬。 |
(c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test). |
|
| S8901 |
Taletrectinib (DS-6051b)Taletrectinib (DS-6051b, AB-106) 是新一代的选择性的ROS1/NTRK 抑制剂，对ROS1，TrkA，TrkB 和TrkC的ic50分别为0.207 nM，0.622 nM，2.28 nM和0.980 nM。 |
||
| S7014 |
Merestinib (LY2801653)Merestinib (LY2801653) 是一种2型ATP竞争型的慢抑制剂，抑制Met (c-Met)酪氨酸激酶，Ki值为2 nM。药效的停留时间为0.00132 min(-1)，t1/2为525 min。Merestinib (LY2801653) 还可抑制MST1R、AXL、ROS1、MKNK1/2、FLT3、MERTK、DDR1和DDR2，其对应的IC50值分别为11 nM、2 nM、23 nM、7 nM、7 nM、10 nM、0.1 nM 和 7 nM。 |
||
| S7998 |
Entrectinib (RXDX-101)Entrectinib (RXDX-101, NMS-E628) 是一种口服生物可利用的泛-TrkA/B/C，ROS1 和 ALK 抑制剂，IC50范围为 0.1~1.7 nM。Entrectinib (RXDX-101) 可诱导自噬。Phase 2。 |
Tumor cells were treated with entrectinib (10 nmol/L) for 4 hours or c-PARP for 48 hours, and harvested lysates were assessed by Western blotting. Data shown are representative of three independent experiments with similar results.
|
|
| S5190New |
Crizotinib hydrochlorideCrizotinib (PF-02341066) hydrochloride (Xalkori) 可抑制 c-Met 和核磷脂(NPM)-anaplastic lymphoma kinase (ALK) 的酪氨酸磷酸化，对应基于细胞的测定中的IC50值分别为 11 nM 和 24 nM。Crizotinib hydrochloride 也是一种有效的 ROS1 的抑制剂，Ki值小于0.025 nM。Crizotinib 可通过抑制多种肺癌细胞系中的STAT3途径诱导自噬。 |
||
| S8583 |
Repotrectinib (TPX-0005)Repotrectinib (TPX-0005) 是一种新型的ALK/ROS1/TRK抑制剂，对WT ALK、ALK(G1202R)、ALK(L1196M)的IC50分别为1.01 nM、1.26 nM、1.08 nM；同时也是一种有效的SRC抑制剂，IC50为5.3 nM。 |
||
| S8229 |
Brigatinib (AP26113)Brigatinib (AP26113) 是一种有效的、选择性的ALK抑制剂，IC50=0.6 nM；也是ROS1抑制剂，IC50=0.9 nM。它还能以相对较低的效力抑制IGF-1R、FLT3、FLT3(D835Y)和EGFR。 |
Immunoblotting analysis of H3122 and H3122-CER cells showing that brigatinib did not inhibit EGFR phosphorylation (p-EGFR). Total EGFR (t-EGFR) is also shown. Actin was used as a loading control. The cells were treated with brigatinib for 2 hours.
|
|
| S8696 |
2-D082-D08 (2',3',4'-trihydroxy flavone) 是一种具有细胞透性的蛋白类泛素化（protein sumoylation）抑制剂。它还能抑制Axl, IRAK4, ROS1, MLK4, GSK3β, RET (c-RET), KDR和PI3Kα，IC50分别为0.49, 3.9, 5.3, 9.8, 11, 11, 17和35 nM。 |
||
| S7536 |
Lorlatinib (PF-6463922)Lorlatinib (PF-6463922)是一个强效的，双重 ALK/ROS1 的抑制剂，对ROS1, ALK (WT), 以及ALK (L1196M)的Ki分别为<0.02 nM, <0.07 nM, 和0.7 nM。PF-06463922 可诱导凋亡。Phase 1。 |
Sub-G1 and cell cycle phase distribution of NBLW and NBLW-R cells treated for 24 hours with DMSO, 1× or 10× the respective GI 50 concentrations of PF-06463922.
|
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S1068 |
Crizotinib (PF-02341066)Crizotinib (PF-02341066) 克唑替尼是一种有效的c-Met和ALK抑制剂，在细胞试验中IC50分别为11 nM 和 24 nM。它同时也是有效的ROS1抑制剂，其Ki值小于0.025 nM。Crizotinib可在多种肺癌细胞系中通过抑制STAT3通路来诱导自噬。 |
(c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test). |
|
| S8901 |
Taletrectinib (DS-6051b)Taletrectinib (DS-6051b, AB-106) 是新一代的选择性的ROS1/NTRK 抑制剂，对ROS1，TrkA，TrkB 和TrkC的ic50分别为0.207 nM，0.622 nM，2.28 nM和0.980 nM。 |
||
| S7014 |
Merestinib (LY2801653)Merestinib (LY2801653) 是一种2型ATP竞争型的慢抑制剂，抑制Met (c-Met)酪氨酸激酶，Ki值为2 nM。药效的停留时间为0.00132 min(-1)，t1/2为525 min。Merestinib (LY2801653) 还可抑制MST1R、AXL、ROS1、MKNK1/2、FLT3、MERTK、DDR1和DDR2，其对应的IC50值分别为11 nM、2 nM、23 nM、7 nM、7 nM、10 nM、0.1 nM 和 7 nM。 |
||
| S7998 |
Entrectinib (RXDX-101)Entrectinib (RXDX-101, NMS-E628) 是一种口服生物可利用的泛-TrkA/B/C，ROS1 和 ALK 抑制剂，IC50范围为 0.1~1.7 nM。Entrectinib (RXDX-101) 可诱导自噬。Phase 2。 |
Tumor cells were treated with entrectinib (10 nmol/L) for 4 hours or c-PARP for 48 hours, and harvested lysates were assessed by Western blotting. Data shown are representative of three independent experiments with similar results.
|
|
| S5190New |
Crizotinib hydrochlorideCrizotinib (PF-02341066) hydrochloride (Xalkori) 可抑制 c-Met 和核磷脂(NPM)-anaplastic lymphoma kinase (ALK) 的酪氨酸磷酸化，对应基于细胞的测定中的IC50值分别为 11 nM 和 24 nM。Crizotinib hydrochloride 也是一种有效的 ROS1 的抑制剂，Ki值小于0.025 nM。Crizotinib 可通过抑制多种肺癌细胞系中的STAT3途径诱导自噬。 |
||
| S8583 |
Repotrectinib (TPX-0005)Repotrectinib (TPX-0005) 是一种新型的ALK/ROS1/TRK抑制剂，对WT ALK、ALK(G1202R)、ALK(L1196M)的IC50分别为1.01 nM、1.26 nM、1.08 nM；同时也是一种有效的SRC抑制剂，IC50为5.3 nM。 |
||
| S8229 |
Brigatinib (AP26113)Brigatinib (AP26113) 是一种有效的、选择性的ALK抑制剂，IC50=0.6 nM；也是ROS1抑制剂，IC50=0.9 nM。它还能以相对较低的效力抑制IGF-1R、FLT3、FLT3(D835Y)和EGFR。 |
Immunoblotting analysis of H3122 and H3122-CER cells showing that brigatinib did not inhibit EGFR phosphorylation (p-EGFR). Total EGFR (t-EGFR) is also shown. Actin was used as a loading control. The cells were treated with brigatinib for 2 hours.
|
|
| S8696 |
2-D082-D08 (2',3',4'-trihydroxy flavone) 是一种具有细胞透性的蛋白类泛素化（protein sumoylation）抑制剂。它还能抑制Axl, IRAK4, ROS1, MLK4, GSK3β, RET (c-RET), KDR和PI3Kα，IC50分别为0.49, 3.9, 5.3, 9.8, 11, 11, 17和35 nM。 |
||
| S7536 |
Lorlatinib (PF-6463922)Lorlatinib (PF-6463922)是一个强效的，双重 ALK/ROS1 的抑制剂，对ROS1, ALK (WT), 以及ALK (L1196M)的Ki分别为<0.02 nM, <0.07 nM, 和0.7 nM。PF-06463922 可诱导凋亡。Phase 1。 |
Sub-G1 and cell cycle phase distribution of NBLW and NBLW-R cells treated for 24 hours with DMSO, 1× or 10× the respective GI 50 concentrations of PF-06463922.
|
沪公网安备 31011502012800号